CXCL10: A candidate biomarker in transplantation

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1364-1373

  Romagnani, Paola ^a   Crescioli, Clara ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

Biomarkers; Chemokines; CXCL10; Transplantation

Indexed keywords

ALPHA CHEMOKINE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 A; CHEMOKINE RECEPTOR CXCR3 ALT; CHEMOKINE RECEPTOR CXCR3 B; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOGENEIC STEM CELL TRANSPLANTATION; BIOPSY; CARDIAC ALLOGRAFT VASCULOPATHY; CELL ACTIVITY; CHEMOTAXIS; CXCL10 GENE; CXCR3 GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE; GENETIC VARIABILITY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; TH1 CELL RECRUITMENT; TRANSPLANT VASCULOPATHY; VASCULAR DISEASE;

ANIMALS; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84861453115     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.02.009     Document Type: Review

References (121)

1. Heidt S., San Sequndo D., Shankar S., Mittal S., Muthusamy A.S., Friend P.J. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011, 92:1-9.
2. Lazzeri E., Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:109-118.
3. Rotondi M., Chovato L., Romagnani S., Serio M., Romagnani P. Role of chemokines in endocrine autoimmune disease. Endocr Soc 2007, 28:492-520.
4. Bonecchi R., Bianchi G.P., Bordignon P.P., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
5. Loetscher M., Gerber B., Loetscher P., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996, 184:963-969.
6. Janatpour M.J., Hudak S., Sathe M., Sedgwick J.D., McEvoy L.M. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med 2001, 194:1375-1384.
7. Penna G., Sozzani S., Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001, 167:1862-1866.
8. Romagnani P., Annunziato F., Lazzeri E., et al. Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCR gamma-delta+ T cells, and natural killer-type cells in human thymus. Blood 2001, 97:601-607.
9. Dyer K.D., Percopo C.M., Fischer E.R., Gabryszewski S.J., Rosenberg H.F. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 2009, 114:2649-2656.
10. Sottili M., Cosmi L., Borgogni E., et al. Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Exp Cell Res 2009, 315:264-273.
11. Romagnani P., Lazzeri E., Lasagni L., et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol 2002, 13:53-64.
12. Crescioli C., Squecco R., Cosmi L., et al. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 2008, 314:1337-1350.
13. Crescioli C., Cosmi L., Borgogni E., et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007, 195:145-155.
14. Crescioli C., Sottili M., Bonini P., Cosmi L., Chiarugi P., Romagnani P., et al. Inflammatory response in human skeletal muscle cells: CXCL10 as potencial therapeutic target. Eur J Cell Biol 2012, 91:139-149.
15. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
16. Rot A., von Adrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004, 22:891-928.
17. Comerford I., Nibbs R.J.B. Post-translational control of chemokines: a role for decoy receptors?. Immunol Lett 2005, 96:163-174.
18. Luster A.D., Ravetch J.V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987, 166:1084-1097.
19. Romagnani P., Annunziato F., Lasagni L., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001, 107:53-63.
20. Romagnani P., Lasagni L., Annunziato F., Serio M., Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004, 25:201-209.
21. Strieter R.M., Polverini P.J., Arenberg D.A., Kunkel S.L. The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4:155-160.
22. Strieter R.M., Kunkel S.L., Shanafeli A.B., Arenberg D.A., Koch A.E., Polverini P.J. CXC chemokines in regulation of angiogenesis. Chemokines in Disease 1996, 195-210.
23. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
24. Luster A.D., Unkeless J.C., Ravetch J.V. γ-Interferon transcriptionally regulate-response gene containing homology to platelet proteins. Nature 1985, 315:672-676.
25. Farber J.M. A macrophage mRNA selectively induced by γ-interferon encodes a member of platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 1990, 87:5238-5242.
26. Cole K.E., Strick C.A., Paradis T.J., et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021.
27. Kouroumalis A., Nibbs R.J., Aptel H., Wright K.L., Kolios G., Ward S.G. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 2005, 175:5403-5411.
28. Lo B.K., Yu M., Zloty D., Cowan B., Shapiro J., McElwee K.J. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010, 176:2435-2446.
29. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001, 12:313-335.
30. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 329:565-568.
31. Marchese A., Heiber M., Nguyen T., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10 and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995, 29:335-344.
32. Loetscher M., Loetscher P., Brass N., Meese E., Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998, 28:3696-3705.
33. Colvin R.A., Campanella G.S., Sun J., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10 and CXCL11 function. J Biol Chem 2004, 279:30219-30227.
34. Qin S., Rottman J.B., Myers P., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101:746-754.
35. Lasagni L., Francalanci M., Annunziato F., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537-1549.
36. Bonacchi A., Romagnani P., Romanelli R.G., et al. Signal transduction by chemokine receptor CXCR3: activation of ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cells migration and proliferation in human vascular pericytes. J Biol Chem 2001, 276:9945-9954.
37. Kawada K., Sonoshita M., Sakashita H., et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004, 64:4010-4017.
38. Kelsen S.G., Aksoy M.O., Yang Y., et al. The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004, 287:L584-L591.
39. Nagaoka K., Nojima H., Watanabe F., et al. Regulation of blastocyst migration, apposition, and initial adhesion by a chemokine, interferon γ-inducible protein 10 kDa (IP-10), during early gastrulation. J Biol Chem 2003, 278:29048-29056.
40. Salcedo R., Resau J.H., Halverson D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000, 14:2055-2064.
41. Rappert A., Bechemann I., Pivneva T., et al. CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci 2004, 24:8500-8509.
42. Belperio J.A., Keane M.P., Arenberg D.A., et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000, 68:1-8.
43. Lloyd C.M., Delaney T., Nguyen T., et al. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp 2000, 191:265-274.
44. Sallusto F., Kremmer E., Palermo B., et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999, 29:2037-2045.
45. Aksoy M.O., Yang Y., Ji R., et al. CXCR3 surface expression in human hairway epithelial cells: cell cycle dependence and effect on cell proliferation. M J Physiol Lung Cell Mol Physiol 2006, 290:L909-L918.
46. Maru S.V., Holloway K.A., Flynn G., et al. Chemokines production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumor cell proliferation. J Neuroimmunol 2008, 199:35-45.
47. Shen Q., Zhang R., Bhat N.R. MAP kinase regulation of IP10/CXCL10 chemokine gene expression in microglial cells. Brain Res 2006, 1086:9-16.
48. Datta D., Flaxenburg J.A., Laxmanan S., et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for development of human breast cancer. Cancer Res 2006, 66:9509-9518.
49. Giuliani N., Bonomini S., Romagnani P., et al. CXCR-3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006, 91:1489-1497.
50. Kim S., Bakre M., Yin H., Varner J.A. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002, 110:933-941.
51. Ji R., Lee C.M., Gonzales L.W., et al. Human type II pneumonocyte chemotactic responses to CXCR3 activation are mediated by splice variant A. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1187-L1196.
52. Engelhardt E., Toksoy A., Goebeler M., Debus S., Brocker E.B., Gillitzer R. Chemokines IL-8, GROα, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol 2008, 153:1849-1860.
53. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004, 173:6234-6240.
54. Christen U., Mc Gavern D.B., Luster A.D., von Herrath M.G., Oldstone M.B. Among CXCR3 chemokines, IFN-gamma-inducible protein 10 KDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003, 171:6838-6845.
55. Arai K., Liu Z.X., Lane T., Dennert G. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell Immunol 2002, 219:48-56.
56. Campbell J.D., Gangur V., Simons F.E., HayGlass K.T. Allergic humans are hyporesponsive to a CXCR3-ligand-mediated Th1 immunity-promoting loop. FASEB 2004, 18:329-331.
57. Smit M.J., Verdijk P., van der Raaij-helmer E.M., et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi-and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 2003, 102:1959-1965.
58. Shahabuddin S., Ji R., Wang P., et al. CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Physiol Cell Physiol 2006, 291:C34-C39.
59. Jinquan T., Jing C., Jacobi H.H., et al. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein 10 and monokine induced by IFN-gamma. J Immunol 2000, 165:1548-1556.
60. Rosenblum J.M., Shimoda N., Schenk A.D., et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol 2010, 184:3450-3460.
61. Heeger P.S. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003, 3:525-533.
62. Hall B.M., Dorsch S.E. Cells mediating allograft rejection. Immunol Rev 1984, 77:31-59.
63. Hidalgo L.G., Halloran P.F. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002, 22:317-349.
64. Larsen C.P., Morris P.J., Austyn J.M. Migration of dendritic leuckocytes from cardiac allografts into host spleen. A novel pathway for initiation of rejection. J Exp Med 1990, 171:307-314.
65. Agostini C., Calabrese F., Rea F., et al. Cxcr3 and its ligand CXCL10 are espresse by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001, 158:1703-1711.
66. Duffner U., Lu B., Hildebrandt G.C., et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003, 31:897-902.
67. El-Sawy T., Fahmy N.M., Fairchild R.L. Chemokines: directing leucocyte infiltration into allograft. Curr Opin Immunol 2002, 14:562-568.
68. Katuka Y., Okumi M., Miyagawa S., Tsutahara K., Abe T., Yazawa K., et al. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. Transplantation 2012, 93:24-31.
69. Fahmy N.M., Yamani M.H., Starling R.C., et al. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003, 75:2044-2047.
70. Fahmy N.M., Yamani M.H., Starling R.C., et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003, 75:72-78.
71. Burns W.R., Wang Y., Tang P.C., Ranjbaran H., Iakimov A., Kim J., et al. Recruitment of CXCR3+ and CXCR5+ T cells and production of interferon-gamma-inducible chemokines in rejection human arteries. Am J Transplant 2005, 6:1226-1236.
72. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 3:1556-1560.
73. Haskova Z., Izawa A., Contreras A.G., Flynn E., Boulday G., Briscoe D.M. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 2007, 83:1595-1601.
74. Halloran P.F., Fairchild R.L. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 2008, 8:1578-1579.
75. Hancock W.W., Lu B., Gao W., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520.
76. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
77. Zhang Z., Kaptanoglu L., Haddad W., et al. Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism. J Immunol 2002, 168:3205-3212.
78. Serger S., Cui Y., Eitner F., et al. Expression of chemokines and chemokines receptors during human renal transplantation rejection. Am Kidney Dis 2001, 37:518-531.
79. Uppaluri R., Sheehan K.C., Wang L., et al. Prolongation of cardiac and islet allograft survival by blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation 2008, 86:137-147.
80. Martinu T., Kinnier C.V., Godwy K.M., et al. Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3. J Heart Lung Transplant 2011, 30:717-725.
81. Belperio J.A., Keane M.P., Burdick M.D., et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002, 169:1037-1049.
82. Medoff B.D., Wain J.C., Seung E., et al. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 2006, 176:7087-7095.
83. Belperio J.A., Keane M.P., Burdick M.D., et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 2003, 171:4844-4852.
84. Westekemper H., Meller S., Citak S., et al. Differential chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant 2004, 45:1340-1346.
85. Piper K.P., Horlock C., Curnow S.J., et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007, 110:3827-3832.
86. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002, 168:3195-3204.
87. Wang X., Yue T.L., Ohlstein E.H., Sung C.P., Feuerstein G.Z. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem 1996, 271:24286-24293.
88. Romagnani P., Beltrame C., Annunziato F., et al. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 1999, 10:2518-2526.
89. Lazzeri E., Lasagni L., Serio M., Romagnani S., Romagnani P. Cytokines and chemokines in nephropathies and renal transplant. G Ital Nefrol 2002, 19:641-649.
90. Stepkowski S.M. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000, 2:1-23.
91. Matl I., Hribova P., Honsova E., Brabcova I., Viklicky O. Potential predictive markers in protocol biopsies for premature renal graft loss. Kidney Blood Press Res 2010, 33:7-14.
92. Lo D.J., Weaver T.A., Kleiner D.E., et al. Chemokines and their receptors in human renal allotransplantation. Transplantation 2011, 91:70-77.
93. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
94. Shahzad K., Cadeiras M., Memon S., Zeeberg B., Klingler T., Sinha A. Gene expression signatures of peripheral blood mononuclear cells during the early post-transplant period in patients developing cardiac allograft vasculopathy. J Transplant 2010, 1-13.
95. Perkins D., Verma M., Park K.J. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 2011, 33:211-218.
96. Lazzeri E., Rotondi M., Mazzinghi B., et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Tranplantation 2005, 79:1215-1220.
97. Rotondi M., Rosati A., Buonamano A., et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004, 4:1466-1474.
98. Hu H., Aizenstein B.D., Puchalski A., Burmania J.A., Hamawy M.M., Knechtle S.J. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004, 4:432-437.
99. Schaub S., Nickerson P., Rush D., et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009, 9:1347-1353.
100. Tatapudi R.R., Muthukumar T., Dadhania D., et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004, 65:2390-2397.
101. Mao Y., Wang M., Zhou Q., et al. CXCL10 and CXCL13 expression were highly up-regulated in peripheral blood mononuclear cells in acute rejection and poor response to anti-rejection therapy. J Clin Immunol 2011, 31:414-418.
102. Rotondi M., Netti G.S., Lazzeri E., et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int 2010, 23:465-475.
103. Heidt S., Shankar S., Muthusamy A.S., San Segundo D., Wood K.J. Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy. Transplantation 2011, 91:e59-e61.
104. Crescioli C., Buonamano A., Scolletta S., et al. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation 2009, 87:249-255.
105. Karason K., Jernas M., Hagg D.A., Svensson P.A. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc Disord 2006, 19:6-29.
106. Hamour I.M., Burke M.M., Bell A.D., Panicker M.G., Banerjee R., Banner N.R. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation 2008, 85:969-974.
107. Hoffman S.A., Wang L., Shah C.V., et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Tranplant 2009, 9:389-396.
108. Scolletta S, Buonamano A, Sottili M, Giomarelli P, Biagioli B, Vannelli GB, et al. CXCL10 release in cardiopulmonary bypass: an in vivo and in vitro study. Biomedicine and Aging Pathology in press, doi:. doi:10.1016/j.biomag.2011.07.001.
109. Berres M.L., Trautwein C., Schmeding M., et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011, 53:596-603.
110. Zeremski M., Petrovic L.M., Chiriboga L., et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
111. Wasmuth H.E., Lammert F., Zaldivar M.M., Weiskirchen R., Hellerbrand C., Scholten D. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 309-19:319.e1-3.
112. Romero A.I., Lagging M., Westin J., et al. Interferon (IFN)-gamma-inducible protein 10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006, 194:895-903.
113. Askarieh G., Alsio A., Pugnale P., et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA overall viral response to therapy in chronic hepatitis C. Hepatology 2010, 51:1523-1530.
114. Roedder S., Vitalone M., Khatri P., Sarwal M.M. Biomarkers in solid organ transplantation : establishing personalized transplantation medicine. Genome Med 2011, 3:37.
115. Osama A.A.G. Gene expression profiling in organ transplantation. Int J Nephrol 2011, 1-5.
116. Khatri P., Sarwal M.M. Using gene arrays in diagnosis of rejection. Curr Opin Organ Transplant 2009, 14:34-39.
117. Sigdel T.K., Sarwal M.M. The proteogenomic path towards biomarker discovery. Pediatr Transplant 2008, 12:737-747.
118. Sigdel T.K., Klassen R.B., Sarwal M.M. Interpreting the proteome and peptidome in transplantation. Adv Clin Chem 2009, 47:139-169.
119. Ying L., Sarwal M. In praise of arrays. Pediatr Nephrol 2009, 24:1643-1659.
120. Anglicheau D., Sharma V.K., Ding R., et al. microRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009, 106:5330-5335.
121. Bodonyi-Kovacs G., Putheti P., Marino M., et al. Gene expression profiling of the donor kidney at the time of transplantation predicts clinical outcomes 2 years after transplantation. Hum Immunol 2010, 71:451-455.